Compare

Repligen Corp vs BioCryst Pharmaceuticals Inc vs ADMA Biologics, Inc. vs Twist Bioscience Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearRepligen Corp
RGEN
BioCryst Pharmaceuticals Inc
BCRX
ADMA Biologics, Inc.
ADMA
Twist Bioscience Corp
TWST
Year ended2025-12-312025-12-312025-12-312026-09-30
Revenue$738.26M$874.84M$510.17M$459.43M
Revenue growth (YoY)+16.4%+94.1%+19.6%+22.0%
Gross margin52.3% (computed)n/a57.4%52.4% (computed)
Operating margin7.5%39.0%37.5%-30.4%
Net margin6.6%30.2%28.8%-28.3%
Net income$48.89M$263.86M$146.93M-$130.20M
EPS (Diluted)$0.86$1.21$0.60-$2.08
Operating cash flow$117.42M$347.37M$50.40M-$41.43M
Free cash flow$93.90M$344.90M$27.82M-$89.01M
Cash & equivalents$566.02M$89.74M$87.63M$533.99M
Total assets$2.95B$514.16M$624.24M$1.12B
Total liabilities$843.57M$633.31M$146.92M$233.79M
Shareholders' equity$2.11B-$119.15M$477.32M$888.02M
Return on year-end equity2.3%n/a30.8%-14.7%
Shares outstanding56.33M213.06M237.87M67.81M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearRepligen CorpBioCryst Pharmaceuticals IncADMA Biologics, Inc.Twist Bioscience Corp
Latest$738.26M
Ended 2025-12-31
$874.84M
Ended 2025-12-31
$510.17M
Ended 2025-12-31
$459.43M
Ended 2026-09-30
1 year earlier$634.44M
Ended 2024-12-31
$450.71M
Ended 2024-12-31
$426.45M
Ended 2024-12-31
$376.57M
Ended 2025-09-30
2 years earlier$632.36M
Ended 2023-12-31
$331.41M
Ended 2023-12-31
$258.21M
Ended 2023-12-31
$312.97M
Ended 2024-09-30
3 years earlier$801.54M
Ended 2022-12-31
$270.83M
Ended 2022-12-31
$154.08M
Ended 2022-12-31
$245.11M
Ended 2023-09-30
4 years earlier$670.53M
Ended 2021-12-31
$157.17M
Ended 2021-12-31
$80.94M
Ended 2021-12-31
$203.56M
Ended 2022-09-30